Biopharmaceutical company argenx SE (ARGX) Monday said preliminary global revenues for its only approved product VYVGART for the treatment of generalized myasthenia gravis (gMG), is expected to be about $374 million for the fourth quarter.
Full-year revenue for VYVGART is expected at $1.2 billion.
As of December 31, 2023, argenx had approximately $3.2 billion in cash, cash equivalents and current financial assets.
For comments and feedback: editorial@rttnews.com